Michigan Parkinson's Disease Clinical Center

描述（由申请人提供）：这是密歇根大学帕金森病临床中心（PDCC）的申请。本PDCC的目标是识别早期轻度帕金森病（PD）受试者，招募他们参加神经保护治疗的试点和大型多组试验，随访招募的受试者直至试验完成，以及试验后随访受试者以确定治疗效果的存在。受试者将从密歇根大学、安阿伯退伍军人事务医疗中心现有的诊所转诊基地招募，通过向密歇根州神经科医生宣传试验，并通过密歇根州主要的非专业PD组织密歇根帕金森基金会（MPF）招募。我们已经在与MPF合作开展全州范围的PD教育和临床护理活动。已建立的合作和全州范围内的活动将加强密歇根州内适当科目的招聘。受试者将入组，并由在临床试验中具有丰富经验的经验丰富的运动障碍临床医生进行随访。我们的中心已经开发出一种有前途的疾病进展的客观标志物; [14 C]二氢丁苯那嗪正电子发射断层扫描（DTBZ-PET）。在我们的研究中心和周围研究中心招募的受试者子集可以使用DTBZ-PET进行连续随访。在初步试验中，该子集可用于评估DTBZ-PET作为疾病状态的生物标志物，并可能作为评估假定神经保护剂的筛选方法。在大型多组试验中，将对一部分患者进行DTBZ-PET随访，作为疾病进展的客观标志物。DTBZ-PET的使用将通过分享密歇根州内其他PDCC的受试者来加强，以确保PET成像的有效使用。

DESCRIPTION (provided by applicant): This is an application for a Parkinson's Disease Clinical Center (PDCC) at the University of Michigan. The goals of this PDCC are identification of subjects with early, mild Parkinson's disease (PD), their recruitment into pilot and large, multi-arm trials of neuroprotective treatments, follow up of recruited subjects until trial completion, and post-trial follow up of subjects to ascertain the presence of treatment effects. Subjects will be recruited from the existing referral base of clinics at the University of Michigan, the Ann Arbor Veterans Affairs Medical Center, via state-wide publicity of the trial to neurologists in Michigan, and through the major lay PD organization in Michigan, the Michigan Parkinson's Foundation (MPF). We are already working with the MPF on statewide educational and clinical care activities for PD. The established collaborations and state-wide range of activities will enhance recruitment of appropriate subjects within Michigan. Subjects will be enrolled and followed by experienced Movement Disorder clinicians with prior significant experience in clinical trials. Our center has developed a promising objective marker of disease progression; [14C]dihydrotetrabenazine positron emission tomography (DTBZ-PET). A subset of subjects recruited at our site and surrounding sites could be followed serially with DTBZ-PET. In pilot trials, this subset could be used to evaluate DTBZ-PET as a biomarker of disease status and possibly as a screening method for evaluation of putative neuroprotective agents. In large, multi-arm trials, a subset of patients would be followed with DTBZ-PET as an objective marker of disease progression. The use of DTBZ-PET will be enhanced by sharing of subjects from other PDCCs within Michigan to ensure efficient use of PET imaging.